Study to Evaluate the Safety and Efficacy of | Clinical Research Studies Listing

Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

Recruiting

18 years - 65 years

All

Phase 1

50 participants needed

1 Location

Brief description of study

The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with the HIV capsid inhibitor lenacapavir (LEN).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: HIV-1
Age: 18 years - 65 years
Gender: All

Male and Female, Age 18-65, On first-line antiretroviral therapy (ART) for ≥ 2 years

Updated on 04 Aug 2024. Study ID: 849990

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

Brief description of study

Eligibility of study

Find a site

Interested in the study